NDAC’s busy schedule
This article was originally published in The Tan Sheet
Executive Summary
A two-day joint meeting of the Nonprescription and Dermatologic & Ophthalmic Drugs Advisory Committees is scheduled for March 24-25. The two committees discussed labeling issues for OTC athlete's foot drugs during a meeting in May (1"The Tan Sheet," May 10, 2004, p. 10). NDAC also is scheduled to meet with the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13-14...
You may also be interested in...
OTC Athlete’s Foot Drug Labeling Changes Supported By NDAC Panel, Industry
Current labeling for OTC drugs for Tinea pedis (athlete's foot) may mislead consumers toward greater expectations of benefit and should be changed, FDA's Nonprescription Drugs and Dermatologic and Ophthalmic Drugs advisory committees agreed unanimously at a May 6 meeting in Rockville, Md
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.